Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis Publisher



Fattahi M1 ; Eskandari N2, 3 ; Sotoodehnejadnematalahi F1 ; Shaygannejad V4 ; Kazemi M5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
  2. 2. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Applied Physiology Research Centre, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Neurology, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Department of Genetic and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Cell Journal Published:2020


Abstract

Objective: Multiple sclerosis (MS) is an inflammatory disease resulting in demyelination of the central nervous system (CNS). T helper 17 (Th17) subset protects the human body against pathogens and induces neuroinflammation, which leads to neurodegeneration. MicroRNAs (miRNAs) are a specific class of small (~22 nt) non-coding RNAs that act as post-transcriptional regulators. The expression of the miR-326 is highly associated with the pathogenesis of MS disease in patients through the promotion of Th17 development. Recently, studies showed that disease-modifying therapies (DMTs) could balance the dysregulation of miRNAs in the immune cells of patients with relapsing-remitting MS (RRMS). Interferon-beta (IFN-β) has emerged as one of the most common drugs for the treatment of RR-MS patients. The purpose of this study was to evaluate the expression of the miR-326 in RRMS patients who were responders and non-responders to IFN-β treatment. Materials and Methods: In this cross-sectional study, a total of 70 patients (35 responders and 35 non-responders) were enrolled. We analyzed the expression of the miR-326 in peripheral blood mononuclear cells (PBMCs) of RRMS patients at least one year after the initiation of IFN-β therapy. Real-time polymerase chain reaction (RT-PCR) was applied to measure the expression of the miR-326. Results: The results showed no substantial change in the expression of the miR-326 between responders and non-responders concerning the treatment with IFN-β. Although the expression of the miR-326 was slightly reduced in IFN-β-responders compared with IFN-β-non-responders; however, the reduction of the miR-326 was not statistically significant. Conclusion: Overall, since IFN-β doesn’t normalize abnormal expression of miR-326, this might suggest that IFN-β affects Th17 development through epigenetic mechanisms other than miR-326 regulation. © 2020 Royan Institute (ACECR). All rights reserved.
Related Docs
View other Related Docs
1. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
2. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
3. Microrna-29B Variants and Mxa Expression Change During Interferon Beta Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2019)
4. The Role of Micrornas Involved in the Disorder of Blood–Brain Barrier in the Pathogenesis of Multiple Sclerosis, Frontiers in Immunology (2023)
5. Mir-145 and Mir20a-5P Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2017)
6. Mir-504 Expression Level Is Increased in Multiple Sclerosis Patients Responder to Interferon-Beta, Journal of Neuroimmunology (2020)
7. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
8. Lncrnas Associated With Multiple Sclerosis Expressed in the Th1 Cell Lineage, Journal of Cellular Physiology (2019)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (55)
Vahid Shaygannejad (43)
Other Related Docs
9. The Effect of Beta Interferon on the Expression of Mir-145 in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2016)
10. Mir-326 and Mir-26A, Two Potential Markers for Diagnosis of Relapse and Remission Phases in Patient With Relapsing-Remitting Multiple Sclerosis, Gene (2014)
11. Micrornas: Key Modulators of Disease-Modifying Therapies in Multiple Sclerosis : Pancreatic Cancer Is One of the Lethal Malignant Tumours in the World.In This Study, We Investigated the Car T-Cell Therapy of Pancreatic Cancer, International Reviews of Immunology (2020)
12. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)
13. Analysis of the Expression of Mir-34A, Mir-199A, Mir-30C and Mir-19A in Peripheral Blood Cd4+T Lymphocytes of Relapsing-Remitting Multiple Sclerosis Patients, Gene (2018)
14. Microrna-92A Drives Th1 Responses in the Experimental Autoimmune Encephalomyelitis, Inflammation (2019)
15. Current Advances in Stem Cell Therapy in the Treatment of Multiple Sclerosis, Reviews in the Neurosciences (2023)
16. Apamin Administration Impact on Mir-219 and Mir-155-3P Expression in Cuprizone Induced Multiple Sclerosis Model, Molecular Biology Reports (2020)
17. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related Micrornas in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2022)
18. Upregulation of Cd4+ T-Cell Derived Mir-223 in the Relapsing Phase of Multiple Sclerosis Patients, Cell Journal (2016)
19. Comparative Analysis of Apigenin-3 Acetate Versus Apigenin and Methyl-Prednisolone in Inhibiting Proliferation and Gene Expression of Th1 Cells in Multiple Sclerosis, Cell Journal (2023)
20. Mir-141 and Mir-200A, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis, PLoS ONE (2015)
21. Potential Biomarker and Therapeutic Lncrnas in Multiple Sclerosis Through Targeting Memory B Cells, NeuroMolecular Medicine (2020)
22. Genetic Variation in Intergenic and Exonic Mirna Sequence and Risk of Multiple Sclerosis in the Isfahan Patients, Iranian Journal of Allergy, Asthma and Immunology (2018)
23. Study of the Correlation Between Mir-106A, Mir-125B, and Mir-330 on Multiple Sclerosis Patients by Targeting Tnfsf4 and Sp1 in Nf-Κb/Tnf-Α Pathway: A Case-Control Study, Cell Journal (2022)
24. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients, Inflammation (2022)
25. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
26. An Integrated Bioinformatics Analysis of the Potential Regulatory Effects of Mir-21 on T-Cell Related Target Genes in Multiple Sclerosis, Avicenna Journal of Medical Biotechnology (2021)
27. Negative Regulation of Semaphorin-3A Expression in Peripheral Blood Mononuclear Cells Using Microrna-497-5P, Iranian Journal of Medical Sciences (2019)
28. Risk Factor Effect of Rs1044165 and Rs3745453 As Neighboring Variants of Mir-223, Mir-24, Mir-23A and Mir-27A on the Onset of Ms Disease in Isfahan/Iran, Gene Reports (2018)
29. Il-23 Plasma Level Measurement in Relapsing Remitting Multiple Sclerosis (Rrms) Patients Compared to Healthy Subjects, Immunological Investigations (2015)
30. Microrna-219 in the Central Nervous System: A Potential Theranostic Approach, Research in Pharmaceutical Sciences (2024)
31. Evaluation of Plasma Osteopontin Level in Relapsing- Remitting Multiple Sclerosis Patients Compared to Healthy Subjects in Isfahan Province, International Journal of Neuroscience (2020)
32. Glutathione Targeted Tragacanthic Acid-Chitosan As a Non-Viral Vector for Brain Delivery of Mirna-219A-5P: An in Vitro/In Vivo Study, International Journal of Biological Macromolecules (2022)
33. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy, Cell Journal (2017)
34. The Levels of Soluble Forms of Cd21 and Cd83 in Multiple Sclerosis, Journal of Neuroimmunology (2018)
35. Multiple Sclerosis and Cerebral Endothelial Dysfunction: Mechanisms, Pathophysiology (2011)
36. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
37. Interdependency of Ninj2 Gene Expression and Polymorphism With Susceptibility and Response to Interferon Beta in Patients With Multiple Sclerosis, International Journal of Neuroscience (2024)
38. Evaluating the Effects of Epigallocatechin-3-Gallate on Hif-1Α Protein and Rorc Gene Expression in Peripheral Blood Mononuclear Cells in Patients With Multiple Sclerosis, Basic and Clinical Neuroscience (2021)
39. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
40. Multiple Sclerosis: Clinical Features, Pathophysiology, Neuroimaging and Future Therapies, Future Neurology (2009)
41. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
42. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
43. Integrative Analysis of Lncrnas in Th17 Cell Lineage to Discover New Potential Biomarkers and Therapeutic Targets in Autoimmune Diseases, Molecular Therapy Nucleic Acids (2018)
44. Evaluation of Plasma Soluble Cd137 Level in Relapsing-Remitting Multiple Sclerosis Patients in Comparison With Healthy Controls in Isfahan Province, Iran, Neurology Asia (2020)
45. The Role of Distinct Subsets of Macrophages in the Pathogenesis of Ms and the Impact of Different Therapeutic Agents on These Populations, Frontiers in Immunology (2021)
46. Therapeutic Effects of Mesenchymal Stem Cells-Derived Extracellular Vesicles’ Mirnas on Retinal Regeneration: A Review, Stem Cell Research and Therapy (2021)
47. The Role of Micrornas in the Pathophysiology of Human Central Nervous System: A Focus on Neurodegenerative Diseases, Ageing Research Reviews (2023)
48. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
49. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
50. Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies, Neurology: Neuroimmunology and NeuroInflammation (2024)